JP2024538573A5 - - Google Patents
Info
- Publication number
- JP2024538573A5 JP2024538573A5 JP2024518745A JP2024518745A JP2024538573A5 JP 2024538573 A5 JP2024538573 A5 JP 2024538573A5 JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024538573 A5 JP2024538573 A5 JP 2024538573A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- region
- fragment
- immunostimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21200496.4 | 2021-10-01 | ||
| EP21200496 | 2021-10-01 | ||
| PCT/EP2022/077270 WO2023052581A1 (en) | 2021-10-01 | 2022-09-30 | Agonistic cd40 antibodies as immune stimulatory agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538573A JP2024538573A (ja) | 2024-10-23 |
| JP2024538573A5 true JP2024538573A5 (cg-RX-API-DMAC7.html) | 2025-10-07 |
Family
ID=78078007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518745A Pending JP2024538573A (ja) | 2021-10-01 | 2022-09-30 | 免疫刺激剤としてのアゴニスト性cd40抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240392026A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4408537A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538573A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118139886A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022358474A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232917A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023052581A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| WO2019057792A1 (en) * | 2017-09-19 | 2019-03-28 | Mab Discovery Gmbh | CD40 ANTIBODY AGONISTS |
-
2022
- 2022-09-30 US US18/696,925 patent/US20240392026A1/en active Pending
- 2022-09-30 AU AU2022358474A patent/AU2022358474A1/en active Pending
- 2022-09-30 CN CN202280066589.8A patent/CN118139886A/zh active Pending
- 2022-09-30 CA CA3232917A patent/CA3232917A1/en active Pending
- 2022-09-30 EP EP22800131.9A patent/EP4408537A1/en active Pending
- 2022-09-30 WO PCT/EP2022/077270 patent/WO2023052581A1/en not_active Ceased
- 2022-09-30 JP JP2024518745A patent/JP2024538573A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7356970B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2021511058A5 (cg-RX-API-DMAC7.html) | ||
| IL272770B1 (en) | CD40 agonist antibodies | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| AU2016281641A1 (en) | Novel PD-1 immune modulating agents | |
| JP2019515008A5 (cg-RX-API-DMAC7.html) | ||
| JP2021528423A5 (cg-RX-API-DMAC7.html) | ||
| FI3736292T3 (fi) | CD3-vasta-aineita ja käyttömenetelmiä | |
| IL313468A (en) | Multi-specific antibodies and methods of making and using thereof | |
| TW201902514A (zh) | Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| FI3452513T3 (fi) | Humanisoituja anti-il-1r3-vasta-aineita | |
| JP2024520666A5 (cg-RX-API-DMAC7.html) | ||
| JP2022545741A5 (cg-RX-API-DMAC7.html) | ||
| JP2020515577A5 (cg-RX-API-DMAC7.html) | ||
| JP2024016024A5 (cg-RX-API-DMAC7.html) | ||
| JP2023519807A5 (cg-RX-API-DMAC7.html) | ||
| JP2024527576A5 (cg-RX-API-DMAC7.html) | ||
| CN117693350A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| NZ761899B2 (en) | Agonistic cd40 antibodies | |
| RU2022118282A (ru) | Новые полипептиды | |
| NZ781933B2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
| RU2024117128A (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4 | |
| NZ781933A (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |